C. Difficile

Barley Chironda, RPN, CIC, discusses current guidance for disinfection practices against C. diff.

A recent study compares the effectiveness of a novel fidaxomicin therapy with vancomycin for the treatment of C. difficile.

Edmond Hooker, MD, DrPH, discusses the cost benefit of investing in launderable hospital mattress covers to prevent CDIs.

In case you missed them, we've compiled the top 5 articles from this past week.

Dr. Richard Vickers, explains how ridinilazole is unique in its spectrum of activity compared with other antibiotics that target C. diff and have been approved or are in development.

Richard Haupt, MD, MPH, discusses what would be required to adequately implement the delivery of a future C. diff vaccine.

Dr. Richard Vickers, explains how antibiotics used to treat C. diff also damage the microbiome.

At the 5th annual international C. diff Awareness Conference and Health Expo, Dr. Edmond Hooker discussed an underreported problem in health care facilities everywhere.

Edmond Hooker, MD, DrPH, discusses the use of a launderable mattress cover to reduce C. diff rates in hospitals.

Investigators from the Baylor College of Medicine in Houston, Texas, have discovered that a common food additive, trehalose (an artificial sugar frequently derived from mushrooms or seaweed), can be linked with the increase and severity of outbreaks involving 2 strains of Clostridium difficile.

Richard Haupt, MD, MPH, sheds light on the Clostridium difficile Vaccine Efficacy Trial (CLOVER).

A recent webinar hosted by the Centers for Disease Control and Prevention and nursing organizations highlighted the important role of nurses in implementing hospital antibiotic stewardship programs.

Dr. Richard Vickers, explains what makes ridinilazole unique.

Michael Edmond, MD, MPH, MPA, stresses that a collaborative effort is needed to control C. difficile in hospitals.

Richard Haupt, MD, MPH, discusses the process for developing a vaccine.

Edmond Hooker, MD, DrPH, explains how regulatory agencies are “turning a blind eye” to an important issue experienced in hospitals everywhere.

Dr. Richard Vickers explains how recurrent infection is an unmet medical need when it comes to C. difficile.

Richard Haupt, MD, MPH, discusses the different pharmaceutical companies’ efforts to develop a C. difficile vaccine.

Authors of a new Policy Forum suggest an alternative approach to regulating fecal microbiota transplantation.

Richard Haupt, MD, MPH, explains how Pfizer is addressing the need for a C. difficile vaccine.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Edmond Hooker, MD, DrPH, discusses how many people have fallen ill or even died due to contaminated hospital mattresses.

Dr. Richard Vickers explains how antibiotics to treat Clostridium difficile infection cause collateral damage to the gut microbiome.

A team of investigators explores if fecal microbiota transplant (FMT) capsules are just as effective as treatment via colonoscopy.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.